Autologous Bone Marrow Mononuclear Cell Transplantation in Treating Type 2 Diabetes Mellitus

A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1026 participants.

Also called NCT01677013

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; no masking; primary purpose treatment
Phase
Phase 1/2
Enrolled
  • 1,026 participants (enrolled count) (from the registry)
Sponsor
Peking University Aerospace Center Hospital (from the registry)
Registry
  • NCT NCT01677013
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01677013. Non-randomized; no masking; primary purpose treatment. Start 2011-05 (registry gives no type); primary completion 2015-05 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Autologous Bone Marrow Mononuclear Cell Transplantation in Treating Type 2 Diabetes Mellitus
Condition
Type 2 Diabetes Mellitus
Intervention (Other)
BMMCT
Lead sponsor
Peking University Aerospace Center Hospital (class: other)

Record details

Record id
cardio:ct-nct01677013
Content hash
ec8b95666a378eafede754639318978833b7a71262125935e6fd9a128aa1e8ec